Ryan D. Maynard is CFO & VP at RIGEL PHARMACEUTICALS INC (RIGL). They have made 7 open-market trades across 2 companies since 2012, most recently 2024-11-12.
CIK 0001363984
1 open-market purchase totalling $51K since 2022, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IOVA | SELL | 2024-11-12 | 2024-11-14 | $10.06 | $503K | +5.7% | -9.2% | -38.1% |
| CARA | SELL · 10b5-1 | 2023-02-08 | 2024-02-12 | $0.53 | $3K | +56.2% | +49.7% | +29.1% |
| IOVA | BUY | 2022-05-31 | 2022-06-02 | $6.75 | $51K | +10.7% | +65.8% | +53.6% |
| RIGL | SELL | 2017-11-03 | 2017-11-07 | $3.90 | $390K | +3.2% | +4.9% | +4.9% |
| RIGL | SELL | 2012-09-12 | 2012-09-14 | $10.67 | $249K | -8.6% | -5.6% | -5.6% |
| RIGL | SELL | 2012-09-07 | 2012-09-11 | $10.54 | $545K | -8.6% | -5.6% | -5.6% |
| RIGL | SELL | 2012-09-07 | 2012-09-14 | $10.67 | $249K | -8.6% | -5.6% | -5.6% |
| RIGL | SELL | 2012-08-07 | 2012-08-09 | $10.61 | $18K | -8.6% | -5.6% | -5.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.